APA (7th ed.) Citation

Silverberg, J. I., Ackerman, L., Bagel, J., Stein Gold, L., Blauvelt, A., Rosmarin, D., . . . Schuster, C. (2026). Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study. Dermatology & Therapy, 16(2), 1309. https://doi.org/10.1007/s13555-025-01644-3

Chicago Style (17th ed.) Citation

Silverberg, Jonathan I., et al. "Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study." Dermatology & Therapy 16, no. 2 (2026): 1309. https://doi.org/10.1007/s13555-025-01644-3.

MLA (9th ed.) Citation

Silverberg, Jonathan I., et al. "Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study." Dermatology & Therapy, vol. 16, no. 2, 2026, p. 1309, https://doi.org/10.1007/s13555-025-01644-3.